An Initiative to Reduce Unnecessary Gadolinium-Based Contrast in Multiple Sclerosis Patients

Jeffrey D. Rudie, Raghav R. Mattay, Matthew Schindler, Samantha Steingall, Tessa S. Cook, Laurie A. Loevner, Mitchell D. Schnall, Alexander Mamourian, Michel Bilello

Research output: Contribution to journalArticle

Abstract

Objective: Patients with multiple sclerosis (MS) routinely undergo serial contrast-enhanced MRIs. Given concerns regarding tissue deposition of gadolinium-based contrast agents (GBCAs) and evidence that enhancement of lesions is only seen in patients with new disease activity on noncontrast imaging, we set out to implement a prospective quality improvement project whereby intravenous contrast would be reserved only for patients with evidence of new disease activity on noncontrast images. Methods: To prospectively implement such a protocol, we leveraged our in-house computer-assisted detection (CAD) software and 3-D laboratory radiology technologists to perform real-time preliminary assessments of the CAD-processed T2 fluid attenuated inversion recovery (FLAIR) noncontrast images as a basis for deciding whether to inject contrast. Before implementation, we held multidisciplinary meetings with neurology, neuroradiology, and MR technologists and distributed surveys to objectively assess opinions and obstacles to clinical implementation. We evaluated reduction in GBCA utilization and technologist performance relative to final neuroradiologist interpretations. Results: During a 2-month trial period, 153 patients were imaged under the new protocol. Technologists using the CAD software were able to identify patients with new or enlarging lesions on FLAIR images with 95% accuracy and 97% negative predictive value relative to final neuroradiologist interpretations, which allowed us to avoid the use of contrast and additional imaging sequences in 87% of patients. Discussion: A multidisciplinary effort to implement a quality improvement project to limit contrast in MS patients receiving follow-up MRIs allowed for improved safety and cost by targeting patients that would benefit from the use of intravenous contrast in real-time.

Original languageEnglish (US)
Pages (from-to)1158-1164
Number of pages7
JournalJournal of the American College of Radiology
Volume16
Issue number9
DOIs
StatePublished - Sep 1 2019

Fingerprint

Gadolinium
Multiple Sclerosis
Quality Improvement
Contrast Media
Software
Neurology
Radiology
Safety
Costs and Cost Analysis

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Cite this

Rudie, J. D., Mattay, R. R., Schindler, M., Steingall, S., Cook, T. S., Loevner, L. A., ... Bilello, M. (2019). An Initiative to Reduce Unnecessary Gadolinium-Based Contrast in Multiple Sclerosis Patients. Journal of the American College of Radiology, 16(9), 1158-1164. https://doi.org/10.1016/j.jacr.2019.04.005
Rudie, Jeffrey D. ; Mattay, Raghav R. ; Schindler, Matthew ; Steingall, Samantha ; Cook, Tessa S. ; Loevner, Laurie A. ; Schnall, Mitchell D. ; Mamourian, Alexander ; Bilello, Michel. / An Initiative to Reduce Unnecessary Gadolinium-Based Contrast in Multiple Sclerosis Patients. In: Journal of the American College of Radiology. 2019 ; Vol. 16, No. 9. pp. 1158-1164.
@article{cab92033be5846efb2b8138518aa400e,
title = "An Initiative to Reduce Unnecessary Gadolinium-Based Contrast in Multiple Sclerosis Patients",
abstract = "Objective: Patients with multiple sclerosis (MS) routinely undergo serial contrast-enhanced MRIs. Given concerns regarding tissue deposition of gadolinium-based contrast agents (GBCAs) and evidence that enhancement of lesions is only seen in patients with new disease activity on noncontrast imaging, we set out to implement a prospective quality improvement project whereby intravenous contrast would be reserved only for patients with evidence of new disease activity on noncontrast images. Methods: To prospectively implement such a protocol, we leveraged our in-house computer-assisted detection (CAD) software and 3-D laboratory radiology technologists to perform real-time preliminary assessments of the CAD-processed T2 fluid attenuated inversion recovery (FLAIR) noncontrast images as a basis for deciding whether to inject contrast. Before implementation, we held multidisciplinary meetings with neurology, neuroradiology, and MR technologists and distributed surveys to objectively assess opinions and obstacles to clinical implementation. We evaluated reduction in GBCA utilization and technologist performance relative to final neuroradiologist interpretations. Results: During a 2-month trial period, 153 patients were imaged under the new protocol. Technologists using the CAD software were able to identify patients with new or enlarging lesions on FLAIR images with 95{\%} accuracy and 97{\%} negative predictive value relative to final neuroradiologist interpretations, which allowed us to avoid the use of contrast and additional imaging sequences in 87{\%} of patients. Discussion: A multidisciplinary effort to implement a quality improvement project to limit contrast in MS patients receiving follow-up MRIs allowed for improved safety and cost by targeting patients that would benefit from the use of intravenous contrast in real-time.",
author = "Rudie, {Jeffrey D.} and Mattay, {Raghav R.} and Matthew Schindler and Samantha Steingall and Cook, {Tessa S.} and Loevner, {Laurie A.} and Schnall, {Mitchell D.} and Alexander Mamourian and Michel Bilello",
year = "2019",
month = "9",
day = "1",
doi = "10.1016/j.jacr.2019.04.005",
language = "English (US)",
volume = "16",
pages = "1158--1164",
journal = "Journal of the American College of Radiology",
issn = "1558-349X",
publisher = "Elsevier BV",
number = "9",

}

Rudie, JD, Mattay, RR, Schindler, M, Steingall, S, Cook, TS, Loevner, LA, Schnall, MD, Mamourian, A & Bilello, M 2019, 'An Initiative to Reduce Unnecessary Gadolinium-Based Contrast in Multiple Sclerosis Patients', Journal of the American College of Radiology, vol. 16, no. 9, pp. 1158-1164. https://doi.org/10.1016/j.jacr.2019.04.005

An Initiative to Reduce Unnecessary Gadolinium-Based Contrast in Multiple Sclerosis Patients. / Rudie, Jeffrey D.; Mattay, Raghav R.; Schindler, Matthew; Steingall, Samantha; Cook, Tessa S.; Loevner, Laurie A.; Schnall, Mitchell D.; Mamourian, Alexander; Bilello, Michel.

In: Journal of the American College of Radiology, Vol. 16, No. 9, 01.09.2019, p. 1158-1164.

Research output: Contribution to journalArticle

TY - JOUR

T1 - An Initiative to Reduce Unnecessary Gadolinium-Based Contrast in Multiple Sclerosis Patients

AU - Rudie, Jeffrey D.

AU - Mattay, Raghav R.

AU - Schindler, Matthew

AU - Steingall, Samantha

AU - Cook, Tessa S.

AU - Loevner, Laurie A.

AU - Schnall, Mitchell D.

AU - Mamourian, Alexander

AU - Bilello, Michel

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Objective: Patients with multiple sclerosis (MS) routinely undergo serial contrast-enhanced MRIs. Given concerns regarding tissue deposition of gadolinium-based contrast agents (GBCAs) and evidence that enhancement of lesions is only seen in patients with new disease activity on noncontrast imaging, we set out to implement a prospective quality improvement project whereby intravenous contrast would be reserved only for patients with evidence of new disease activity on noncontrast images. Methods: To prospectively implement such a protocol, we leveraged our in-house computer-assisted detection (CAD) software and 3-D laboratory radiology technologists to perform real-time preliminary assessments of the CAD-processed T2 fluid attenuated inversion recovery (FLAIR) noncontrast images as a basis for deciding whether to inject contrast. Before implementation, we held multidisciplinary meetings with neurology, neuroradiology, and MR technologists and distributed surveys to objectively assess opinions and obstacles to clinical implementation. We evaluated reduction in GBCA utilization and technologist performance relative to final neuroradiologist interpretations. Results: During a 2-month trial period, 153 patients were imaged under the new protocol. Technologists using the CAD software were able to identify patients with new or enlarging lesions on FLAIR images with 95% accuracy and 97% negative predictive value relative to final neuroradiologist interpretations, which allowed us to avoid the use of contrast and additional imaging sequences in 87% of patients. Discussion: A multidisciplinary effort to implement a quality improvement project to limit contrast in MS patients receiving follow-up MRIs allowed for improved safety and cost by targeting patients that would benefit from the use of intravenous contrast in real-time.

AB - Objective: Patients with multiple sclerosis (MS) routinely undergo serial contrast-enhanced MRIs. Given concerns regarding tissue deposition of gadolinium-based contrast agents (GBCAs) and evidence that enhancement of lesions is only seen in patients with new disease activity on noncontrast imaging, we set out to implement a prospective quality improvement project whereby intravenous contrast would be reserved only for patients with evidence of new disease activity on noncontrast images. Methods: To prospectively implement such a protocol, we leveraged our in-house computer-assisted detection (CAD) software and 3-D laboratory radiology technologists to perform real-time preliminary assessments of the CAD-processed T2 fluid attenuated inversion recovery (FLAIR) noncontrast images as a basis for deciding whether to inject contrast. Before implementation, we held multidisciplinary meetings with neurology, neuroradiology, and MR technologists and distributed surveys to objectively assess opinions and obstacles to clinical implementation. We evaluated reduction in GBCA utilization and technologist performance relative to final neuroradiologist interpretations. Results: During a 2-month trial period, 153 patients were imaged under the new protocol. Technologists using the CAD software were able to identify patients with new or enlarging lesions on FLAIR images with 95% accuracy and 97% negative predictive value relative to final neuroradiologist interpretations, which allowed us to avoid the use of contrast and additional imaging sequences in 87% of patients. Discussion: A multidisciplinary effort to implement a quality improvement project to limit contrast in MS patients receiving follow-up MRIs allowed for improved safety and cost by targeting patients that would benefit from the use of intravenous contrast in real-time.

UR - http://www.scopus.com/inward/record.url?scp=85069944004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069944004&partnerID=8YFLogxK

U2 - 10.1016/j.jacr.2019.04.005

DO - 10.1016/j.jacr.2019.04.005

M3 - Article

C2 - 31092348

AN - SCOPUS:85069944004

VL - 16

SP - 1158

EP - 1164

JO - Journal of the American College of Radiology

JF - Journal of the American College of Radiology

SN - 1558-349X

IS - 9

ER -